

Obesity and Pregnancy as Risk Factors for Influenza and Pneumonia

Padma Jyesta, Terry Oroszi*

Department of Pharmacology & Toxicology, Boonshoft School of Medicine, Wright State University, Fairborn, OH, USA
Email: *terry.oroszi@wright.edu

How to cite this paper: Jyesta, P. and Oroszi, T. (2024) Obesity and Pregnancy as Risk Factors for Influenza and Pneumonia. *Health*, 16, 1304-1314.
<https://doi.org/10.4236/health.2024.1612090>

Received: March 20, 2024
Accepted: December 27, 2024
Published: December 30, 2024

Copyright © 2024 by author(s) and Scientific Research Publishing Inc.
This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).
<http://creativecommons.org/licenses/by/4.0/>



Open Access

Abstract

Pregnancy and obesity have been identified as risk factors for severe influenza and pneumonia. These populations experience higher rates of respiratory complications, including pulmonary distress, hospitalization, and mortality. While the exact mechanisms for this increased susceptibility remain unclear, evidence suggests that the altered immune response in pregnant and obese individuals may play a significant role. This review aims to provide an overview of the impact of obesity and pregnancy on influenza and pneumonia, examining the risk factors, causes, management strategies, and the efficacy of antiviral treatments. Additionally, we explore the potential immunological processes contributing to the severity of these infections in these high-risk groups.

Keywords

Pregnancy, Obesity, Influenza, Pneumonia, Risk Factors, Antiviral, Vaccines

1. Introduction

Pregnancy and obesity are two conditions that weaken the immune system, increasing the likelihood of multiple diseases, including H1N1pdm09 virus influenza infection. Influenza infection in pregnant and obese patients can lead to critical illnesses such as diabetes, asthma, and lung damage, and in severe cases, hospitalization [1]. Other risk factors include altered immune functionality and acquired respiratory infections. The immune system weakening and dysregulation are due to the Th1 response in obesity and the Th2 response in pregnancy [2]. The adverse effects of influenza are significant in obese and pregnant patients, leading to high mortality rates [3].

Obesity is linked to lower lung function and chronic respiratory problems, increasing the risk of severe influenza infection. Peer-reviewed journals indicate that

vaccine efficacy is significantly higher when administered correctly. In pregnant patients, the correct vaccine dosage reduces hospitalization risk but decreases antibody production in obese individuals. Vaccines are effective when given at the right time and in the correct doses to pregnant and obese patients. This review discusses the risk factors, causes, management, treatment, and efficiencies of antiviral drugs to provide insight into these areas.

Influenza and pneumonia are significant respiratory illnesses affecting millions worldwide each year, leading to complications ranging from mild discomfort to severe respiratory distress, hospitalization, and death. Certain populations, including pregnant women and obese individuals, face an elevated risk of severe outcomes from these infections. Pregnancy induces immune suppression and various physiological changes in the respiratory system, making pregnant women particularly vulnerable to severe influenza and pneumonia infections. Influenza infection during pregnancy can also increase the risk of adverse fetal outcomes, including premature birth and low birth weight.

Obesity, a growing global health concern, impairs immune function and leads to chronic low-grade inflammation, compromising respiratory health and making obese individuals more susceptible to severe influenza and pneumonia. Obesity is also linked to an increased risk of comorbidities, such as diabetes and cardiovascular disease, which can exacerbate the severity of respiratory infections.

This review aims to comprehensively assess the current literature on the impact of pregnancy and obesity on influenza and pneumonia. It delves into the risk factors, explores the underlying causes, and discusses effective management strategies, including antiviral therapies and vaccination. Additionally, it examines the potential immunological mechanisms contributing to the heightened severity of these infections in high-risk populations and obesity are two conditions that weaken the immune system, increasing the likelihood of multiple diseases, including H1N1pdm09 virus influenza infection. Influenza infection in pregnant and obese patients can lead to critical illnesses such as diabetes, asthma, and lung damage, and in severe cases, hospitalization [1]. Other risk factors include altered immune functionality and acquired respiratory infections. Obesity favors a pro-inflammatory Th1 response, while pregnancy shifts towards a Th2-dominant environment to protect the fetus, increasing susceptibility to certain infections [2]. The adverse effects of influenza are significant in obese and pregnant patients, leading to high mortality rates [3]. Obesity is linked to lower lung function and chronic respiratory problems, increasing the risk of severe influenza infection. Peer-reviewed journals indicate that vaccine efficacy is significantly higher when administered correctly. In pregnant patients, the correct vaccine dosage reduces hospitalization risk but decreases antibody production in obese individuals. Vaccines are effective when given at the right time and in the correct doses to pregnant and obese patients.

Influenza and pneumonia are significant respiratory illnesses affecting millions worldwide each year, leading to complications ranging from mild discomfort to

severe respiratory distress, hospitalization, and death. Certain populations, including pregnant women and obese individuals, face an elevated risk of severe outcomes from these infections. Pregnancy induces immune suppression and various physiological changes in the respiratory system, making pregnant women particularly vulnerable to severe influenza and pneumonia infections. Influenza infection during pregnancy can also increase the risk of adverse fetal outcomes, including premature birth and low birth weight. Obesity, a growing global health concern, impairs immune function and leads to chronic low-grade inflammation, compromising respiratory health and making obese individuals more susceptible to severe influenza and pneumonia. Obesity is also linked to an increased risk of comorbidities, such as diabetes and cardiovascular disease, which can exacerbate the severity of respiratory infections.

This review aims to comprehensively assess the current literature on the impact of pregnancy and obesity on influenza and pneumonia. It delves into the risk factors, explores the underlying causes, and discusses effective management strategies, including antiviral therapies and vaccination. Additionally, it examines the potential immunological mechanisms contributing to the heightened severity of these infections in high-risk populations.

2. Methods

To conduct this review, a comprehensive search strategy was implemented, utilizing PubMed and Google Scholar as the primary databases. Relevant keywords, including “influenza,” “pneumonia,” “obesity,” “pregnancy,” and “risk factors,” were employed to identify pertinent studies. Boolean operators were used to refine the search results. The search was limited to articles published in the last decade, focusing on human subjects to ensure the currency and relevance of the information gathered.

While a systematic review process was initially planned, the heterogeneity of the available literature, including variations in study design and outcome measures, led to the adoption of a modified approach. This modified systematic review process allowed for the inclusion of a broader range of studies, enhancing the scope and comprehensiveness of the review.

The selection of articles followed a two-stage process. In the initial stage, titles and abstracts were screened to exclude studies that were clearly outside the scope of the review. In the second stage, full-text articles were retrieved and assessed for inclusion based on pre-defined criteria, such as relevance to the review’s focus on influenza and pneumonia in obese and pregnant populations.

Data extraction from the included studies focused on key themes, including the risk factors, causes, management strategies, and treatment outcomes of influenza and pneumonia in obese and pregnant populations. A standardized data extraction form was used to ensure consistency and accuracy in capturing relevant information. Outcomes of influenza and pneumonia in obese and pregnant populations.

3. Risk Factors

3.1. Obesity

Obesity is a significant risk factor for pneumonia due to impaired oxygen flow and immune surveillance. It is estimated that 30% of Americans are obese, while in European countries, a quarter of men and women are also obese. Obesity leads to chronic health problems such as type 2 diabetes mellitus, hypertension, cardiovascular diseases, and several types of cancer, which exacerbate the risk of infectious diseases. Factors like immune system dysregulation, decreased cell-mediated responses, and respiratory dysfunction increase the risk of severe influenza and pneumonia [4]. The fatality rate of pneumonia in obese people is high because overall body fat restricts respiratory function significantly [5]. Obesity is linked to higher counts of lymphocyte and leukocyte subsets, except for certain T cells, and increased monocyte and granulocyte activity [6].

Obese individuals often experience sleep apnea, pulmonary embolism, and aspiration pneumonia. Chronic hypoventilation and inflammation in the respiratory tract further increase the risk of acute lung infections, requiring hospitalization and mechanical ventilation [7] [8]. Systematic reviews indicate that obesity is directly linked to pneumonia, especially in patients with influenza A(H1N1)pmd09 infection, leading to higher mortality and ICU hospitalization rates [4] [9]. The World Health Organization (WHO) reports a significant relationship between obesity, influenza, and pneumonia, with 70,000 H1N1 cases from 20 countries showing a clear link [10].

3.2. Pregnancy

Pregnancy involves changes in respiratory physiology to meet the increased needs of the mother and fetus, such as increased edema, chest wall modifications, and reduced functional residual capacity. However, it also leads to immunologic suppression, increasing vulnerability to infections. Influenza prevention requires adaptive immune responses, and the immune system's tolerance of the fetal allograft involves changes in cellular immunological response [1].

Pregnancy is a severe risk factor for influenza infections, with higher mortality rates in pregnant women. Effective management includes antiviral treatments to protect both mother and fetus. Studies show that pregnant women with influenza have higher hospitalization rates compared to non-pregnant women [11].

Despite appropriate vaccination, pregnant women are more likely to require critical care due to increased lung oxygen demands and physical strain on the lungs during the second and third trimesters. The physiological changes during pregnancy, such as increased edema and modifications to the chest wall and diaphragm, contribute to these risks. Immunologic suppression during pregnancy also increases vulnerability to various infections [1].

Pregnancy as a Risk Factor for Severe Outcomes from Influenza Virus Infection

Pregnancy is considered a severe risk factor for influenza infections. Peer-

reviewed journals and articles state that influenza infection leads to higher mortality rates in pregnant women. Effective management of the disease in acute cases includes antiviral treatments to protect both mother and fetus. Systematic reviews and meta-analyses indicate that pregnant women with influenza have higher hospitalization rates compared to non-pregnant women [11].

With the appropriate dosage of vaccine, the mortality rates of pregnant women are lower. However, ecological studies also indicate that pregnant women have a higher chance of hospitalization. Risk factors are mainly for people under sixty years. Some systematic reviews also link obesity to pneumonia, but risk factors vary considerably [9].

Periodic reviews state that obesity is directly linked to pneumonia when patients suffer from influenza A(H1N1)pmd09 infection. The mortality rates in hospitals increase due to influenza A(H1N1)pmd09 infection in obese persons. ICU hospitalizations also increase due to influenza and pneumonia, leading to higher death rates. According to the World Health Organization (WHO), there is a significant relationship between obesity, influenza, and pneumonia. The WHO reported 70,000 cases of H1N1 from 20 countries, indicating a clear link between obesity and influenza [4].

4. Causes of Influenza in Obesity and Pregnancy

4.1. Viral Strains and the Role of Antiviral Drugs

Influenza viruses, particularly strains like H1N1pdm09, are known to cause severe illness in both obese and pregnant individuals. The severity of influenza can lead to the development of antiviral resistance, making treatment challenging. However, several effective antiviral drugs are available, including neuraminidase inhibitors like Oseltamivir, Zanamivir, Peramivir, and the recently FDA-approved endonuclease inhibitor *Baloxavir marboxil*. These drugs have shown high efficacy in treating influenza, particularly in obese patients, and are generally safe for use in pregnancy. Prompt initiation of antiviral treatment is crucial for optimal outcomes. Studies indicate that early treatment, within 48 hours of illness onset, is most effective. However, antiviral treatment can still be beneficial even when started later, especially in hospitalized patients and pregnant women [9].

4.2 How Pregnancy and Obesity Exacerbate Infections

Obesity is a primary factor contributing to pneumonia due to impaired oxygen flow and immune surveillance. It is estimated that 30% of Americans are obese, while in European countries, a quarter of men and women are also obese. Obesity leads to chronic health problems such as type 2 diabetes mellitus, hypertension, cardiovascular diseases, and several types of cancer, which exacerbate the risk of infectious diseases. Factors like immune system dysregulation, decreased cell-mediated responses, and respiratory dysfunction increase the risk of severe influenza and pneumonia [4].

Higher levels of adipokines, such as leptin, are increased in obese persons, while

adiponectin decreases pro-inflammatory cytokine production and restricts macrophage activities. This pathophysiology weakens the immune system, making it hyper-responsive to pathogens. The cytokines released in the human body are pro-inflammatory, leading to the development of influenza A (H1N1) pdm09 infection [12]. In some acute cases, this can result in sepsis. The role of antivirals is substantial in controlling and managing influenza and pneumonia in obese individuals. The standard dose of Oseltamivir is beneficial for critically ill obese patients, but adequacy is often required to cure terminally sick patients [13].

Obesity also leads to chronic health problems such as type 2 diabetes mellitus, hypertension, cardiovascular diseases, and several types of cancer, which worsen the outcomes of infectious illnesses. Factors increasing the risk of influenza infection in obese people include immune system dysregulation, decreased cell-mediated immune responses, related comorbidities, respiratory dysfunction, and pharmacological issues [4]. The fatality rate of pneumonia in obese people is high due to restricted respiratory function [5].

Pregnancy involves physiological changes, such as increased edema and modifications to the chest wall, that can impact respiratory function. Additionally, pregnancy induces a state of immune suppression to tolerate the developing fetus, making pregnant women more susceptible to infections. This immune suppression can lead to severe complications from influenza, including higher hospitalization rates and adverse fetal outcomes like premature birth and low birth weight.

4.3. Vaccination Strategies

Management strategies for obese individuals with pneumonia and influenza include prompt antiviral treatment and annual vaccination. Individuals with a BMI ≥ 30 , particularly those with a BMI ≥ 40 , are more prone to flu and pneumonia, leading to hospital admission and death due to the severity of the H1N1 virus [9]. Antiviral therapy is highly effective during influenza, but the critical management option is annual vaccination to restrict the spread of the disease. Vaccinations are less effective in obese people, so adequate dosage and robust treatment options are essential to reduce fatalities and mortalities [1].

Obesity is caused by a constant state of meta-inflammation, which has systemic implications for immunity. When infected with the influenza virus, obese hosts have delayed and muted antiviral responses, recovering slowly. Weight loss programs, dietary changes, and exercise are the first lines of defense against the obesity epidemic. Despite this, there is no evidence that these measures help obese people fight viruses. Obesity's rising prevalence is concerning, as infection of an obese host may soon overtake infection of a healthy-weight host as the most common cause of infection. Severe influenza pandemics are projected to become more common as viral shedding, transmission, and the introduction of novel virus variations increase. Obesity management will enhance the quality of life for millions of individuals affected and reduce the risk of infection [8].

Vertical transmission of influenza, from mother to fetus, poses additional risks.

This can lead to adverse neonatal outcomes, including premature birth, low birth weight, and fetal distress. The impact of vertical transmission on the developing fetus underscores the importance of preventative measures, such as vaccination, for pregnant women.

Vaccination is a crucial preventative measure for both pregnant and obese individuals. However, the effectiveness of vaccines can be influenced by these conditions. In pregnant women, vaccination can reduce the risk of hospitalization, but it may also lead to lower antibody production. For obese individuals, vaccines may be less effective, requiring careful consideration of dosage and timing to optimize protection.

5. Efficacies of Antiviral Drugs

Antiviral drugs are the best way to treat influenza and pneumonia among sufferers. The severity of influenza is so high that it gained resistance to all the drugs available. Among the best antiviral drugs are Oseltamivir, Zanamivir, Peramivir, and the recently FDA-approved *Baloxavir marboxil*, an endonuclease inhibitor [14].

These drugs have shown high efficacy in treating influenza, particularly in obese patients, and are generally safe for use in pregnancy. Oseltamivir is highly recommended by practitioners for pregnant patients to treat the flu, as it restricts severity and reduces the chance of hospitalization [15].

Antiviral medication should begin as soon as feasible because studies show that treatment started early (within 48 hours of illness onset) is more likely to be effective. However, other studies have found that antiviral treatment is beneficial even when started more than 48 hours after the onset of the illness, especially in hospitalized patients and pregnant women [16] [17].

The above discussion shows that influenza antivirals are effective when patients are highly affected by the disease. Antivirals help reduce complications, leading to accurate and efficient management of influenza illness and bacterial pneumonia. The use of Oseltamivir therapy improved the survival rate from 0% to 75% significantly [18]. No severe side effects from Oseltamivir treatment have been observed in pregnant women [19].

On the other hand, treatment with rimantadine was ineffective due to a lower survival ratio. Treatment with ampicillin is efficient in curbing infection, but the dosage is not fully curing the disease. However, the addition of Oseltamivir with ampicillin improved the survival rates of patients [20]. Increased understanding of the link between obesity and severe influenza virus pathogenesis may have led to faster antiviral treatment of obese patients, potentially reducing disease severity [21].

Zanamivir and Oseltamivir are renowned drugs for the treatment and management of influenza. These medicines are highly effective immediately after diagnosis. If used after 48 hours of symptoms, they provide negligible or no results. However, they are highly effective if patients have adequate immunodeficiency and

progressive respiratory disease [22]. More research is needed to determine how successful our present antivirals are at reaching infected tissue and shielding obese populations from severe disease [23].

The treatment with antivirals has shown to be more effective in treating and managing the disease in children. In children, these therapies work comprehensively, reducing acute symptoms of influenza significantly within 36 hours. Antibiotic treatment did not show significant results in treating influenza and pneumonia, with efficiencies reduced by 25% [24]. In adults, the use of antiviral therapy reduces complications within 24 hours, leading to an enhanced quality of life [25].

These drugs are highly effective in treating and managing obese patients with influenza and pneumonia. It is also vital to analyze the use and efficiencies of antivirals in pregnant situations to gain insights into the therapy's efficacy in different scenarios. Medical reports state that Zanamivir is the best choice for pregnant women due to its robust efficacy [26]. Zanamivir is administered by inhalation, avoiding significant changes in blood levels making it safer for pregnant women.

However, Oseltamivir requires thorough administration and care in lactating women because the effects of the drug on human milk are unknown [27]. Treating the disease with antiviral drugs varies in each aspect. In obese adults and children, less effective drugs were effective in pregnant women and vice versa. Adequate management and treatment of the disease significantly restrict mortality rates in pregnant women and obese individuals.

6. Management and Treatment of Pregnant Women with Influenza and Pneumonia

The use of antiviral drugs is the best way to prevent the severity of influenza in pregnant women. Antivirals reduce the chance of hospitalization and shorten the duration of hospital stays. Accurate antiviral treatment helps restrict the multiplication of viruses in the body, preventing the immune system from weakening during pregnancy. Immediate action is required within 48 hours of the onset of flu symptoms in pregnant women for optimal effectiveness [4].

The type of treatment for maternal pneumonia depends on whether the illness is caused by a virus or bacteria. Most viral pneumonia therapies are deemed safe to use during pregnancy, and early detection usually means antiviral treatment can cure the infection. A doctor may also recommend respiratory treatments. If bacterial pneumonia develops, antibiotics may be prescribed.

Acetaminophen and other over-the-counter pain relievers can help lower a fever and manage pain. However, it is critical to consult with a doctor to determine whether these medications are safe to take during pregnancy. Additionally, getting enough rest and staying hydrated will help speed up recovery [28].

7. Conclusions

The risk of severe outcomes from influenza and pneumonia is significantly

elevated in obese and pregnant populations. Effective management, including antiviral treatment and vaccination, is crucial in mitigating these risks and improving quality of life. Both conditions present unique challenges, but timely intervention and ongoing research are essential to combat the increased susceptibility to these infections.

Obesity and pregnancy both weaken the immune system, increasing the risk of severe influenza and pneumonia. Antiviral drugs, such as Oseltamivir and Zanamivir, are effective in treating these infections, especially when administered early. Vaccination is a critical preventative measure, though its effectiveness can vary in obese and pregnant individuals. Preventative measures, including vaccination and early antiviral treatment, are vital in reducing the incidence and severity of influenza and pneumonia in high-risk populations. Maintaining a healthy lifestyle, managing chronic conditions, and seeking timely medical advice can further mitigate these risks.

Healthcare providers and policymakers must prioritize the development and dissemination of effective treatment and prevention strategies for influenza and pneumonia in obese and pregnant populations. Continued research and public health initiatives are essential to protect these vulnerable groups and improve overall health outcomes.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

- [1] Karlsson, E.A., Marcelin, G., Webby, R.J. and Schultz-Cherry, S. (2012) Pregnancy and Influenza. *Immunological Reviews*, **248**, 206-221.
- [2] He, Z., Li, Y., Rong, Y., Xie, J., Wu, X. and Ai, Q. (2017) The Potential Role of Macrophages in Obesity-Associated Insulin Resistance and Fatty Liver Disease. *Journal of Immunology Research*, **2017**, Article ID: 1748035.
- [3] Aebi, C., Jensen, T., Bingisser, R. and Hochstrasser, B. (2010) Seasonal Influenza Vaccine and the Risk of Community-Acquired Pneumonia Requiring Hospitalization in Adults: A Meta-Analysis of Case-Control Studies. *Vaccine*, **28**, 7234-7240.
- [4] Green, W.D. and Beck, M.A. (2017) Obesity Impairs the Adaptive Immune Response to Influenza Virus. *Annals of the American Thoracic Society*, **14**, S406-S409. <https://doi.org/10.1513/annalsats.201706-447aw>
- [5] Bal, A.M., Ma, S.F., Van, L.T., Huy, N.T., Van, P.C., Thuy, N.T.H., Farrar, J.J. and Hien, T.T. (2012) Increased Risk of Severe Influenza A (H5N1) Virus Infection among Hospitalized Patients with Obesity in Vietnam. *The American Journal of Tropical Medicine and Hygiene*, **87**, 1109-1116.
- [6] Rivera-Carranza, T., Nájera-Medina, O., Bojalil-Parra, R., Rodríguez-López, C.P., Zúñiga-León, E., León-Téllez Girón, A., *et al.* (2023) The Link between Lymphocyte Subpopulations in Peripheral Blood and Metabolic Variables in Patients with Severe Obesity. *Peer J*, **11**, e15465. <https://doi.org/10.7717/peerj.15465>
- [7] Barthelemy, A., Elias, J., Scalfaro, P. and Schwebel, C. (2016) Impact of Obesity on Influenza A Virus Infection Severity. *Metabolism*, **65**, 34-42.

- [8] Honce, R. and Schultz-Cherry, S. (2016) Impact of Obesity on Influenza A Virus Pathogenesis, Immune Response, and Evolution. *Viruses*, **8**, Article 181.
- [9] Louie, J.K. (2009) Factors Associated with Death or Hospitalization Due to Pandemic 2009 Influenza A(H1N1) Infection in California. *Journal of the American Medical Association*, **305**, 1766-1744. <https://doi.org/10.1001/jama.2009.1583>
- [10] WHO (2017) Influenza (Seasonal). World Health Organization. [https://www.who.int/en/news-room/fact-sheets/detail/influenza-\(seasonal\)](https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal))
- [11] Wolfe, D.M., Fell, D., Garritty, C., Hamel, C., Butler, C., Hersi, M., *et al.* (2023) Safety of Influenza Vaccination during Pregnancy: A Systematic Review. *BMJ Open*, **13**, e066182. <https://doi.org/10.1136/bmjopen-2022-066182>
- [12] Mazunina, E.P., Gushchin, V.A., Bykonina, E.N., Kleymenov, D.A., Siniavin, A.E., Kozlova, S.R., *et al.* (2024) Immunogenicity and Efficacy of Combined mRNA Vaccine against Influenza and Sars-Cov-2 in Mice Animal Models. *Vaccines*, **12**, 1206. <https://doi.org/10.3390/vaccines12111206>
- [13] Bertias, G., Manolakis, A.C. and Boumpas, D.T. (2014) Obesity, the Complement System, and Rheumatic Diseases. *Current Opinion in Rheumatology*, **26**, 108-116.
- [14] Dhakal, S. and Klein, E.Y. (2019) Global Patterns of Influenza Antiviral Resistance. *Viruses*, **11**, Article 733.
- [15] Ehrenstein, V., Kristensen, N.R., Monz, B.U., Clinch, B., Kenwright, A. and Sørensen, H.T. (2018) Antiviral Medication for Influenza in Pregnancy and Breastfeeding. *Cochrane Database of Systematic Reviews*, **2018**, CD011501.
- [16] Muthuri, S.G., Venkatesan, S., Myles, P.R., Leonardi-Bee, J., Al Khuwaitir, T.S.A., Al Mamun, A., *et al.* (2014) Effectiveness of Neuraminidase Inhibitors in Reducing Mortality in Patients Admitted to Hospital with Influenza a H1N1pdm09 Virus Infection: A Meta-Analysis of Individual Participant Data. *The Lancet Respiratory Medicine*, **2**, 395-404. [https://doi.org/10.1016/s2213-2600\(14\)70041-4](https://doi.org/10.1016/s2213-2600(14)70041-4)
- [17] Godoy, P., Soldevila, N., Martínez, A., Godoy, S., Jané, M., Torner, N., *et al.* (2024) Effectiveness of Influenza Vaccination and Early Antiviral Treatment in Reducing Pneumonia Risk in Severe Influenza Cases. *Vaccines*, **12**, Article 173. <https://doi.org/10.3390/vaccines12020173>
- [18] William, D.M. (2005) Clinical Practice. High-Dose Oseltamivir in Human Influenza. *New England Journal of Medicine*, **353**, 2667-2672.
- [19] Koenig, K.L. (2005) Oseltamivir-Resistant Influenza—Challenges in Pandemic Preparedness Planning. *New England Journal of Medicine*, **353**, 2657-2660.
- [20] Leiva-Juarez, M.M., García-García, L., Ormsby, C.E., Pérez-Guzmán, C., Zúñiga, J., González-León, M. and López-Gatell, H. (2018) Oseltamivir Plus Ampicillin-Sulbactam vs Ampicillin-Sulbactam Alone for Treatment of Influenza in Hospitalized Adults: A Randomized Clinical Trial. *Journal of the American Medical Association*, **320**, 1117-1126.
- [21] Segaloff, R.E., Falk, J.D., House, J.M., Shoham, S., Mou, H., Jansen, E.A. and Isern, S. (2018) Obesity Promotes Severe Influenza A Virus Pathogenesis and Impairs the Antiviral Response. *mBio Journal*, **9**, e00991-18.
- [22] Ghoneim, H.E. and McCullers, J.A. (2014) Obesity and Pandemic H1N1 Influenza Outcomes. *Current Opinion in Pulmonary Medicine*, **20**, 228-234.
- [23] Jefferson, T., Jones, M.A., Doshi, P., Del Mar, C.B., Hama, R., Thompson, M.J. and Spencer, E.A. (2014) Neuraminidase Inhibitors for Preventing and Treating Influenza in Healthy Adults and Children. *Cochrane Database of Systematic Reviews*, **2014**, CD008965.

- [24] Goodnight, W.H. and Soper, D.E. (2005) Pneumonia in Pregnancy. *Critical Care Medicine*, **33**, S390-S397. <https://doi.org/10.1097/01.ccm.0000182483.24836.66>
- [25] Hewagama, S., Walker, S.P., Stuart, R.L., Gordon, C., Johnson, P.D.R., Friedman, N.D., *et al.* (2010) 2009 H1N1 Influenza A and Pregnancy Outcomes in Victoria, Australia. *Clinical Infectious Diseases*, **50**, 686-690. <https://doi.org/10.1086/650460>
- [26] Vollaard, A., Schreuder, I., Slok-Raijmakers, L., Opstelten, W., Rimmelzwaan, G. and Gelderblom, H. (2017) Influenza Vaccination in Adult Patients with Solid Tumours Treated with Chemotherapy. *European Journal of Cancer*, **76**, 134-143. <https://doi.org/10.1016/j.ejca.2017.02.012>
- [27] Jiva, T.M. (2000). Critical Care of Pregnant Women, Part 2: Fluid and Air Embolism, Pneumonia: A Guide to Risk Factors, Preventive Measures, and Treatment Options. *Journal of Critical Illness*, **15**, 424-429.
- [28] Murphy, R., Fragaszy, E.B., Hayward, A.C. and Warren-Gash, C. (2016) Investigating Obesity as a Risk Factor for Influenza-Like Illness during the 2009 H1N1 Influenza Pandemic Using the Health Survey for England. *Influenza and Other Respiratory Viruses*, **11**, 66-73. <https://doi.org/10.1111/irv.12420>